Physician profile
June Halper
NPI 1548256092
$358,320.15
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,000 · 2022: $2,410 · 2023: $204K · 2024: $150K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $350K · Consulting Fee: $2,779 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $610 · Food and Beverage: $508 · Education: $12.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $350,000.00 |
| Consulting Fee | $2,779.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $610.00 |
| Food and Beverage | $508.21 |
| Education | $12.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $350,047.03 | 2021-2024 | |
| Emd Serono, INC. | $3,585.09 | 2021-2023 | Mavenclad |
| Hexal Ag | $1,834.25 | 2023 | |
| Merck Kgaa | $945.00 | 2023 | Evobrutinib |
| Cycle Pharmaceuticals INC | $610.00 | 2023 | |
| Janssen Global Services, LLC | $580.00 | 2021-2022 | |
| Tg Therapeutics, INC. | $189.40 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $151.88 | 2023 | |
| Celgene Corporation | $127.54 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.98 | 2021 | |
| Banner Life Sciences, LLC | $124.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw June Halper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.